Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma

Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodefic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of general virology 2024-11, Vol.105 (11)
Hauptverfasser: Byren, Hannah C, Holzer, Angela, Müller, Alexander, Korn, Klaus, Backovic, Marija, Harrer, Ellen G, Bergmann, Silke, Harrer, Thomas, Neipel, Frank
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 11
container_start_page
container_title Journal of general virology
container_volume 105
creator Byren, Hannah C
Holzer, Angela
Müller, Alexander
Korn, Klaus
Backovic, Marija
Harrer, Ellen G
Bergmann, Silke
Harrer, Thomas
Neipel, Frank
description Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.
doi_str_mv 10.1099/jgv.0.002044
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3130828403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3130828403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c178t-955ec82700edea18be23a97bb7e225d5432c33d226924e2d51df624a594c345d3</originalsourceid><addsrcrecordid>eNo9kE1Lw0AQhhdRbK3ePMve9GDqfubjKMWPYsGLXryEze6kTUmycacp6K83kuppmHkfXoaHkEvO5pxl2d12vZ-zOWOCKXVEplzFOhJDcEymw1FEXPJkQs4Qt4xxpXRySiYy07EWPJuSj2VrAxgERzd9Y1q6gdAB7qvQY5TSFvpdMHX1XbVrGgA73yJQ14dxbyrEyre0DL6hL6bzWF0jRROsb8w5OSlNjXBxmDPy_vjwtniOVq9Py8X9KrI8SXdRpjXYVCSMgQPD0wKENFlSFAkIoZ1WUlgpnRBxJhQIp7krY6GMzpSVSjs5Izdjbxf8Zw-4y4e3LNS1acH3mEsuWSpSxeSA3o6oDR4xQJl3oWpM-Mo5y39t5oPNnOWjzQG_OjT3RQPuH_7TJ38A_wxw8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130828403</pqid></control><display><type>article</type><title>Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma</title><source>MEDLINE</source><source>Microbiology Society</source><creator>Byren, Hannah C ; Holzer, Angela ; Müller, Alexander ; Korn, Klaus ; Backovic, Marija ; Harrer, Ellen G ; Bergmann, Silke ; Harrer, Thomas ; Neipel, Frank</creator><creatorcontrib>Byren, Hannah C ; Holzer, Angela ; Müller, Alexander ; Korn, Klaus ; Backovic, Marija ; Harrer, Ellen G ; Bergmann, Silke ; Harrer, Thomas ; Neipel, Frank</creatorcontrib><description>Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.</description><identifier>ISSN: 0022-1317</identifier><identifier>ISSN: 1465-2099</identifier><identifier>EISSN: 1465-2099</identifier><identifier>DOI: 10.1099/jgv.0.002044</identifier><identifier>PMID: 39565219</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Antibodies, Neutralizing - blood ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Female ; Herpesvirus 8, Human - immunology ; HIV Infections - immunology ; HIV Infections - virology ; Humans ; Male ; Middle Aged ; Sarcoma, Kaposi - immunology ; Sarcoma, Kaposi - virology</subject><ispartof>Journal of general virology, 2024-11, Vol.105 (11)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c178t-955ec82700edea18be23a97bb7e225d5432c33d226924e2d51df624a594c345d3</cites><orcidid>0009-0005-9929-1198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3733,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39565219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Byren, Hannah C</creatorcontrib><creatorcontrib>Holzer, Angela</creatorcontrib><creatorcontrib>Müller, Alexander</creatorcontrib><creatorcontrib>Korn, Klaus</creatorcontrib><creatorcontrib>Backovic, Marija</creatorcontrib><creatorcontrib>Harrer, Ellen G</creatorcontrib><creatorcontrib>Bergmann, Silke</creatorcontrib><creatorcontrib>Harrer, Thomas</creatorcontrib><creatorcontrib>Neipel, Frank</creatorcontrib><title>Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma</title><title>Journal of general virology</title><addtitle>J Gen Virol</addtitle><description>Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.</description><subject>Adult</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Female</subject><subject>Herpesvirus 8, Human - immunology</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Sarcoma, Kaposi - immunology</subject><subject>Sarcoma, Kaposi - virology</subject><issn>0022-1317</issn><issn>1465-2099</issn><issn>1465-2099</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1Lw0AQhhdRbK3ePMve9GDqfubjKMWPYsGLXryEze6kTUmycacp6K83kuppmHkfXoaHkEvO5pxl2d12vZ-zOWOCKXVEplzFOhJDcEymw1FEXPJkQs4Qt4xxpXRySiYy07EWPJuSj2VrAxgERzd9Y1q6gdAB7qvQY5TSFvpdMHX1XbVrGgA73yJQ14dxbyrEyre0DL6hL6bzWF0jRROsb8w5OSlNjXBxmDPy_vjwtniOVq9Py8X9KrI8SXdRpjXYVCSMgQPD0wKENFlSFAkIoZ1WUlgpnRBxJhQIp7krY6GMzpSVSjs5Izdjbxf8Zw-4y4e3LNS1acH3mEsuWSpSxeSA3o6oDR4xQJl3oWpM-Mo5y39t5oPNnOWjzQG_OjT3RQPuH_7TJ38A_wxw8w</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Byren, Hannah C</creator><creator>Holzer, Angela</creator><creator>Müller, Alexander</creator><creator>Korn, Klaus</creator><creator>Backovic, Marija</creator><creator>Harrer, Ellen G</creator><creator>Bergmann, Silke</creator><creator>Harrer, Thomas</creator><creator>Neipel, Frank</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0005-9929-1198</orcidid></search><sort><creationdate>202411</creationdate><title>Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma</title><author>Byren, Hannah C ; Holzer, Angela ; Müller, Alexander ; Korn, Klaus ; Backovic, Marija ; Harrer, Ellen G ; Bergmann, Silke ; Harrer, Thomas ; Neipel, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c178t-955ec82700edea18be23a97bb7e225d5432c33d226924e2d51df624a594c345d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Female</topic><topic>Herpesvirus 8, Human - immunology</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Sarcoma, Kaposi - immunology</topic><topic>Sarcoma, Kaposi - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Byren, Hannah C</creatorcontrib><creatorcontrib>Holzer, Angela</creatorcontrib><creatorcontrib>Müller, Alexander</creatorcontrib><creatorcontrib>Korn, Klaus</creatorcontrib><creatorcontrib>Backovic, Marija</creatorcontrib><creatorcontrib>Harrer, Ellen G</creatorcontrib><creatorcontrib>Bergmann, Silke</creatorcontrib><creatorcontrib>Harrer, Thomas</creatorcontrib><creatorcontrib>Neipel, Frank</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of general virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Byren, Hannah C</au><au>Holzer, Angela</au><au>Müller, Alexander</au><au>Korn, Klaus</au><au>Backovic, Marija</au><au>Harrer, Ellen G</au><au>Bergmann, Silke</au><au>Harrer, Thomas</au><au>Neipel, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma</atitle><jtitle>Journal of general virology</jtitle><addtitle>J Gen Virol</addtitle><date>2024-11</date><risdate>2024</risdate><volume>105</volume><issue>11</issue><issn>0022-1317</issn><issn>1465-2099</issn><eissn>1465-2099</eissn><abstract>Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.</abstract><cop>England</cop><pmid>39565219</pmid><doi>10.1099/jgv.0.002044</doi><orcidid>https://orcid.org/0009-0005-9929-1198</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-1317
ispartof Journal of general virology, 2024-11, Vol.105 (11)
issn 0022-1317
1465-2099
1465-2099
language eng
recordid cdi_proquest_miscellaneous_3130828403
source MEDLINE; Microbiology Society
subjects Adult
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Female
Herpesvirus 8, Human - immunology
HIV Infections - immunology
HIV Infections - virology
Humans
Male
Middle Aged
Sarcoma, Kaposi - immunology
Sarcoma, Kaposi - virology
title Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A21%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20human%20herpesvirus-8%20neutralizing%20response%20during%20remission%20from%20Kaposi's%20sarcoma&rft.jtitle=Journal%20of%20general%20virology&rft.au=Byren,%20Hannah%20C&rft.date=2024-11&rft.volume=105&rft.issue=11&rft.issn=0022-1317&rft.eissn=1465-2099&rft_id=info:doi/10.1099/jgv.0.002044&rft_dat=%3Cproquest_cross%3E3130828403%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130828403&rft_id=info:pmid/39565219&rfr_iscdi=true